LONDON (Alliance News) - GlaxoSmithKline PLC and its partner Innoviva Inc on Thursday said the phase three Captain study of once-daily single inhaler triple therapy Trelegy Ellipta met its primary endpoint.
The drugmaker said Trelegy Ellipta was compared to Relvar/Breo Ellipta in the treatment of patients living with uncontrolled asthma. The study demonstrated a statistically "significant" improvement in lung function.
"We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available. We plan to submit these data for regulatory review after the full dataset is available," said Hal Barron, Glaxo's chief scientific officer & president of Research & Development.
"The Captain study has shown that triple therapy in a single inhaler provides a potential new treatment option for asthma management in patients uncontrolled on ICS/LABA," added Vice President of Respiratory Medicine at Innoviva Paul Meunier.
LABA monotherapy increases the risk of serious asthma-related events.
Glaxo shares closed 0.7% lower in London on Thursday at 1,548.96 pence each.